354 related articles for article (PubMed ID: 28417160)
1. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist
Wieser G; Popp I; Christian Rischke H; Drendel V; Grosu AL; Bartholomä M; Weber WA; Mansi R; Wetterauer U; Schultze-Seemann W; Meyer PT; Jilg CA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1463-1472. PubMed ID: 28417160
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Prospective Evaluation of
Minamimoto R; Sonni I; Hancock S; Vasanawala S; Loening A; Gambhir SS; Iagaru A
J Nucl Med; 2018 May; 59(5):803-808. PubMed ID: 29084827
[No Abstract] [Full Text] [Related]
4. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
[TBL] [Abstract][Full Text] [Related]
5. Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET.
Stoykow C; Erbes T; Maecke HR; Bulla S; Bartholomä M; Mayer S; Drendel V; Bronsert P; Werner M; Gitsch G; Weber WA; Stickeler E; Meyer PT
Theranostics; 2016; 6(10):1641-50. PubMed ID: 27446498
[TBL] [Abstract][Full Text] [Related]
6. Value of
Beheshti M; Taimen P; Kemppainen J; Jambor I; Müller A; Loidl W; Kähkönen E; Käkelä M; Berndt M; Stephens AW; Minn H; Langsteger W
Eur Radiol; 2023 Jan; 33(1):472-482. PubMed ID: 35864350
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of [
Fassbender TF; Schiller F; Mix M; Maecke HR; Kiefer S; Drendel V; Meyer PT; Jilg CA
Nucl Med Biol; 2019 Mar; 70():32-38. PubMed ID: 30836254
[TBL] [Abstract][Full Text] [Related]
8. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer.
Schollhammer R; de Clermont Gallerande H; Robert G; Yacoub M; Vimont D; Hindié E; Fernandez P; Morgat C
Clin Nucl Med; 2019 Sep; 44(9):e535-e536. PubMed ID: 31246685
[TBL] [Abstract][Full Text] [Related]
10. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A
J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
Jilg CA; Drendel V; Rischke HC; Beck T; Vach W; Schaal K; Wetterauer U; Schultze-Seemann W; Meyer PT
Theranostics; 2017; 7(6):1770-1780. PubMed ID: 28529650
[No Abstract] [Full Text] [Related]
12.
Duan H; Moradi F; Davidzon GA; Liang T; Song H; Loening AM; Vasanawala S; Srinivas S; Brooks JD; Hancock S; Iagaru A
Lancet Oncol; 2024 Apr; 25(4):501-508. PubMed ID: 38423030
[TBL] [Abstract][Full Text] [Related]
13. PET Using a GRPR Antagonist
Zhang J; Niu G; Fan X; Lang L; Hou G; Chen L; Wu H; Zhu Z; Li F; Chen X
J Nucl Med; 2018 Jun; 59(6):922-928. PubMed ID: 29123014
[TBL] [Abstract][Full Text] [Related]
14. Correlation of
Duan H; Baratto L; Fan RE; Soerensen SJC; Liang T; Chung BI; Thong AEC; Gill H; Kunder C; Stoyanova T; Rusu M; Loening AM; Ghanouni P; Davidzon GA; Moradi F; Sonn GA; Iagaru A
J Nucl Med; 2022 Dec; 63(12):1829-1835. PubMed ID: 35552245
[No Abstract] [Full Text] [Related]
15. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
17. GRPr Antagonist
Bakker IL; Fröberg AC; Busstra MB; Verzijlbergen JF; Konijnenberg M; van Leenders GJLH; Schoots IG; de Blois E; van Weerden WM; Dalm SU; Maina T; Nock BA; de Jong M
J Nucl Med; 2021 Nov; 62(11):1517-1523. PubMed ID: 33789933
[TBL] [Abstract][Full Text] [Related]
18. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
19. PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
Baratto L; Song H; Duan H; Hatami N; Bagshaw HP; Buyyounouski M; Hancock S; Shah S; Srinivas S; Swift P; Moradi F; Davidzon G; Iagaru A
J Nucl Med; 2021 Nov; 62(11):1545-1549. PubMed ID: 33674398
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
